Retinitis Pigmentosa Market

Market Overview:

The retinitis pigmentosa market reached a value of USD 9.5 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 18.5 Billion by 2035, exhibiting a growth rate (CAGR) of 6.22% during 2025-2035.

The retinitis pigmentosa market has been comprehensively analyzed in IMARC's new report titled "Retinitis Pigmentosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Retinitis pigmentosa is a group of genetic eye disorders that primarily affect the retina, which is the light-sensitive tissue at the back of the eye. It typically causes progressive degeneration of the photoreceptor cells in the retina, leading to vision loss and, eventually, blindness. The disorder affects rods and cones, the two types of photoreceptor cells responsible for vision in low-light and bright-light conditions, respectively. The ailment typically causes night blindness, followed by tunnel vision and loss of central vision. Various other symptoms include difficulty distinguishing colors, glare sensitivity, and reduced visual acuity. As the disease progresses, it can lead to more severe visual impairment. The ailment is typically diagnosed through a comprehensive eye examination that comprises a visual acuity test, a visual field test, an electroretinogram (ERG), and genetic testing to identify any known mutations associated with the disease. During the examination, an eye care professional will evaluate the health of the retina and look for characteristic changes, such as the presence of pigmentation and the thinning of blood vessels. They may also perform additional tests to assess visual function, such as color vision testing and contrast sensitivity testing.

The rising cases of mutations in various genes that are involved in the function and maintenance of the retina are primarily driving the retinitis pigmentosa market. Additionally, the increasing prevalence of several triggering factors, such as genetic predisposition, certain medical conditions like Usher syndrome, exposure to environmental toxins, etc., is also propelling the market growth. Besides this, the widespread adoption of antioxidant therapy that involves taking supplements, including vitamin C, vitamin E, coenzyme Q10, etc., to reduce the levels of oxidative stress in the retina is creating a positive outlook for the market. Moreover, the emerging popularity of retinal prostheses, which use electrical stimulation to activate the remaining cells in the retina, allowing patients to distinguish between light and dark, is acting as another significant growth-inducing factor. Apart from this, the rising usage of fundus photography in diagnosing the ailment by detecting changes in the appearance of the retina, such as the presence of bone spicules, is also augmenting the market growth. Furthermore, the escalating demand for RNA therapy to slow or halt the progression of the condition, as well as improve visual function and quality of life for affected individuals, is expected to drive the retinitis pigmentosa market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the retinitis pigmentosa market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for retinitis pigmentosa and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the retinitis pigmentosa market in any manner.

Key Highlights:

• Retinitis Pigmentosa is the most prevalent inherited retinal dystrophy, affecting over 1.5 million individuals globally.
• Retinitis pigmentosa is generally categorized into syndromic and non-syndromic disease.
• Non-syndromic retinitis pigmentosa is the type of disease without systemic abnormalities, and it accounts for 70-80% of all cases.
• Patients with retinitis pigmentosa frequently suffer sleep difficulties due to a lack of photic input (as much as 76% of patients) and headaches.
• Retinitis Pigmentosa affects 1 in every 4000 people in the United States.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the retinitis pigmentosa market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the retinitis pigmentosa market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current retinitis pigmentosa marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the retinitis pigmentosa market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the retinitis pigmentosa across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the retinitis pigmentosa across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of retinitis pigmentosa across the seven major markets?
• What is the number of prevalent cases (2019-2035) of retinitis pigmentosa by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of retinitis pigmentosa by gender across the seven major markets?
• What is the number of prevalent cases (2019-2035) of retinitis pigmentosa by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with retinitis pigmentosa across the seven major markets?
• What is the size of the retinitis pigmentosa patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of retinitis pigmentosa?
• What will be the growth rate of patients across the seven major markets?

Retinitis Pigmentosa: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for retinitis pigmentosa drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the retinitis pigmentosa market?
• What are the key regulatory events related to the retinitis pigmentosa market?
• What is the structure of clinical trial landscape by status related to the retinitis pigmentosa market?
• What is the structure of clinical trial landscape by phase related to the retinitis pigmentosa market?
• What is the structure of clinical trial landscape by route of administration related to the retinitis pigmentosa market?